Synlogic, Inc. (SYBX)
Stock Price:
$2.00 USD
-0.03 (-1.48%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
68.33M |
| Revenue (ttm) |
2.08M |
| Net Income (ttm) |
-57.45M |
| Shares Out |
34.17M |
| EPS (ttm) |
-1.67 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$2.00 |
| Previous Close |
$2.03 |
| Change ($) |
-0.03 |
| Change (%) |
-1.48% |
| Day's Open |
2.03 |
| Day's Range |
1.99 - 2.13 |
| Day's Volume |
375,596 |
| 52-Week Range |
1.35 - 3.46 |
More Stats
| Market Cap |
68.33M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.17M |
| Float |
20.13M |
| EPS (basic) |
-1.66 |
| EPS (diluted) |
-1.67 |
| FCF / Share |
-1.26 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
274,725 |
| Short Ratio |
1.82 |
| Short % of Float |
1.36% |
| Beta |
1.94 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
32.84 |
| PB Ratio |
0.53 |
| Revenue |
2.08M |
| Operating Income |
-59.95M |
| Net Income |
-57.45M |
| Free Cash Flow |
-44.11M |
| Net Cash |
86.22M |
| Net Cash / Share |
2.52 |
| Gross Margin |
-703.56% |
| Operating Margin |
-2,880.92% |
| Profit Margin |
-2,760.50% |
| FCF Margin |
-2,119.51% |
| ROA |
-20.02% |
| ROE |
-36.77% |
| ROIC |
-33.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
6 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$7.57*
(278.50% upside)
Low
2.00
Current: $2.00
High
13.00
Target: 7.57
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 2.22 | 2.52 | 2.44 | 0.44 | - | - | - | - |
| Revenue Growth | -11.75% | 3.11% | 450.45% | - | - | - | - | - |
| Gross Profit | 2.22 | 2.52 | 2.44 | 0.44 | - | - | - | - |
| Operating Income | -54.41 | -51.23 | -40.82 | -20.96 | -25.03 | -13.91 | -6.78 | -4.30 |
| Net Income | -51.37 | -48.44 | -40.38 | -20.95 | -24.98 | -15.83 | -6.44 | -3.66 |
| Shares Outstanding | 30.28 | 23.88 | 6.72 | 2.98 | 0.72 | 0.01 | - | - |
| Earnings Per Share | -1.70 | -2.03 | -6.00 | - | -40.95 | -2,036.96 | -30,859.93 | -2,614.79 |
| Operating Cash Flow | -75.47 | -42.47 | -31.06 | -20.41 | -21.14 | -13.97 | -6.50 | -4.52 |
| Capital Expenditures | -1.25 | -5.65 | -2.57 | -1.83 | -0.25 | -0.10 | -0.01 | - |
| Free Cash Flow | -76.72 | -48.12 | -33.62 | -22.24 | -21.39 | -14.07 | -6.50 | -4.52 |
| Cash & Equivalents | 121 | 124 | 88.12 | 14.64 | 89.71 | 9.32 | 9.32 | - |
| Total Debt | 25.01 | 0.48 | 0.89 | 0.38 | - | - | - | - |
| Net Cash / Debt | 95.65 | 123 | 87.23 | 14.26 | 89.71 | 9.32 | 9.32 | - |
| Assets | 189 | 140 | 99.70 | 20.04 | 90.92 | 9.83 | 9.83 | - |
| Liabilities | 31.67 | 16.24 | 14.66 | 11.54 | 5.90 | 2.50 | 2.50 | - |
| Book Value | 157 | 124 | 85.04 | 8.50 | 85.02 | -47.95 | -47.95 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Synlogic, Inc. |
| Country |
United States |
| Employees |
76 |
| CEO |
Aoife M. Brennan |
Stock Information
| Ticker Symbol |
SYBX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SYBX |
Description
Synlogic, a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.